Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:G01N AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20040235047Methods for treatment of severe acute respiratory syndrome (SARS)
US 25.11.2004
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Appl.No 10441059 Applicant Wyeth Holdings Corporation Inventor Siber George R.

Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.

2.1020080012449SAFE AND ACCURATE DIAGNOSTIC METHODS FOR SARS BY USING NUCLEOCAPSIDE OR SPIKE PROTEIN OF SARS-CoV MUTATED CORONAVIRUS AS AN ANTIGEN
KR 12.02.2008
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Appl.No 1020060073275 Applicant SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION Inventor PARK, JAE HAK
PURPOSE: Diagnostic methods for SARS(severe acute respiratory syndrome) by using nucleocapside or spike protein are provided to improve the safety and accuracy of diagnosis and allow early diagnosis, so that they are applicable to general laboratories and hospitals without a risk of infection. CONSTITUTION: A method for diagnosis of SARS comprises the steps of: amplifying a gene encoding SARS-CoV-N(SARS coronavirus-nucleocapsid protein) and amplifying the amplified gene to Escherichia coli to produce an SARS-CoV-N antigen; producing an antibody against the SARS-CoV-N antigen; and reacting a specimen containing the SARS-CoV-N antibody coupled with a coloring material such as enzyme or gold and the SARS-CoV antigen with a membrane adsorbing the SARS-CoV-N antibody. A diagnostic kit contains the membrane adsorbing the SARS-CoV-N antibody and solution containing the SARS-CoV-N antibody coupled with a coloring material. A method for preparing SARS-CoV-S(SARS coronavirus-spike protein) antigen comprises the steps of: amplifying a gene encoding SARS-CoV-S antigen and inserting the amplified gene into a vector; transfecting 293 T cell with an expression vector containing SARS-CoV-S antigen; and infecting the transformed 293 T cell with VSV(vesicular stomatitis vesicle) to produce SARS-CoV-S antigen. Further, the antibody is a single clone antibody. ©KIPO 2008
3.20050276818Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
US 15.12.2005
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
Appl.No 11132142 Applicant The Burnham Institute Inventor Godzik Adam

The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus. The present invention also relates to diagnostic assays for identifying and characterizing a strain of coronavirus as being one causing severe acute respiratory syndrome.

4.WO/2008/045120TRANSGENIC MOUSE LINES EXPRESSING HUMAN ACE2 AND USES THEREOF
WO 17.04.2008
Int.Class C12N 15/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Appl.No PCT/US2007/000744 Applicant THE BOARD OF TRUSTEES OF THE UNIVERSITY OF TEXAS SYSTEM AND CHAN ET AL Inventor CHAN, Teh-Sheng
Animal models for severe acute respiratory syndrome (SARS)-coronavirus infection of humans are needed to elucidate SARS pathogenesis and develop vaccines and antivirals. Transgenic mice were developed expressing human angiotensin-converting enzyme 2, a functional receptor for the virus, under the regulation of a global promoter. A transgenic lineage, designated AC70, was among the best characterized against SARS coronavirus infection, showing weight loss and other clinical manifestations before reaching 100% mortality within 8 days after intranasal infection. High virus titers were detected in the lungs and brains of transgene-positive mice on days 1 and 3 after infection. Inflammatory mediators were also detected in these tissues, coinciding with high levels of virus replication. In contrast, infected transgene-negative mice survived without showing any clinical illness. The severity of the disease developed in these transgenic mice, AC70 in particular, makes these mouse models valuable not only for evaluating the efficacy of antivirals and vaccines, but also for studying SARS coronavirus pathogenesis and infection by other coronaviruses utilizing human ACE2 for viral entry into cells.
5.20150275183Human Betacoronavirus lineage C and identification of N-terminal dipeptidyl peptidase as its virus receptor
US 01.10.2015
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No 14430010 Applicant Erasmus University Medical Center Rotterdam Inventor Bartholomeus Leonardus Haagmans

The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus classifiable as belonging to the Order: Nidovirales; Family: Coronaviridae; Subfamily: Coronavirinae; Genus: Betacoronavirus; and non-Lineage A, non-Lineage B or non-Lineage D, human betacoronavirus. The invention also provides a human virus having a receptor binding domain (RBD) capable of binding to a dipeptidyl peptidase 4. The invention also provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.

6.20050037338Method and means for detection of severe acute respiratory syndrome
US 17.02.2005
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
Appl.No 10640032 Applicant Inventor Tseng Kuo-Tang

A diagnostic means and method of detecting the presence or the absence of severe acute respiratory syndrome coronavirus antibody in a test sample. The means comprises a solid support, an unlabeled recombinant antigen peptide on a first area of the solid support, a labeled recombinant antigen peptide on a second area of the solid support and an internal control antibody peptide on a third area of the solid phase. The first area is located between the second and the third area.

7.2611106ANTI-CORONAVIRUS MOLECULES AND THEIR USE IN COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING INFECTION CAUSED BY A CORONAVIRUS
CA 20.05.2008
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No 2611106 Applicant HONG-KONG PASTEUR RESEARCH CENTRE Inventor NAL-ROGIER, BEATRICE THERESE MARIE
The present invention relates to the field of coronavirus and more particularly to anti-coronavirus molecules and their use in compositions and methods for treating and/or preventing infection caused by a coronavirus such as the one responsible for SARS. The present invention also relates to a method for screening new anti- coronavirus molecules.

8.20060110758Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
US 25.05.2006
Int.Class C12Q 1/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Appl.No 11262044 Applicant The University of Hong Knog Inventor Zheng Bojian

The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR.

9.WO/2008/062309ANTI-CORONAVIRUS MOLECULES AND THEIR USE IN COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING INFECTION CAUSED BY A CORONAVIRUS
WO 29.05.2008
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/IB2007/004174 Applicant HONG-KONG PASTEUR RESEARCH CENTRE Inventor NAL-ROGIER, Béatrice, Thérèse, Marie
The present invention relates to the field of coronavirus and more particularly to anti-coronavirus molecules and their use in compositions and methods for treating and/or preventing infection caused by a coronavirus such as the one responsible for SARS. The present invention also relates to a method for screening new anti- coronavirus molecules.
10.20080014204Compositions against SARS-coronavirus and uses thereof
US 17.01.2008
Int.Class C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Appl.No 11667640 Applicant Crucell Holland B.V. Inventor Ter Meulen Jan Henrik

The present invention provides compositions of binding molecules specifically binding to a coronavirus such as SARS-CoV and capable of neutralizing an infection caused by the virus. The compositions are suitable for diagnosing, preventing and/or treating a condition resulting from a coronavirus such as SARS-CoV.